Key result
Review summarizes mechanisms of myocardial interstitial fibrosis in HF and the need for personalized antifibrotic therapies.
Why the study?
Translation of basic knowledge on myocardial interstitial fibrosis to improved diagnostics and therapeutics for heart failure has been limited by a paucity of biomarkers and personalized antifibrotic strategies.
This review summarizes the mechanisms, biomarkers, and potential therapies for myocardial interstitial fibrosis in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Caution advised in biomarker-guided management of fibrotic HF; leaves open development of personalized antifibrotic therapies.
González et al. (2018) conducted a review in Heart failure and myocardial interstitial fibrosis. This review summarizes the mechanisms of myocardial interstitial fibrosis in heart failure, highlighting the critical need for novel biomarkers and personalized antifibrotic therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: